What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline |
| [23-October-2026] |
Complaint alleges Unicycive Therapeutics, Inc. misled investors between December 29, 2025 and June 29, 2026; investors may seek lead plaintiff role by November 2, 2026 LOS ANGELES, Oct. 23, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class action lawsuit covers investors who bought Unicycive Therapeutics, Inc. ("Unicycive Therapeutics" or the "Company") (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. The Unicycive Therapeutics, Inc. case, Patel v. Unicycive Therapeutics, Inc., was filed on September 3, 2026 in the U.S. District Court for the Northern District of California (Case No. 26-cv-09559).
Investors who suffered losses on Unicycive Therapeutics, Inc. investments can submit their Unicycive Therapeutics, Inc. loss information here before the November 2, 2026 lead plaintiff deadline. Key dates in the Unicycive Therapeutics, Inc. case
What happened? On June 30, 2026, Unicycive Therapeutics disclosed that the FDA had issued a second Complete Response Letter regarding the Company's resubmitted New Drug Application for its kidney disease therapy, oxylanthanum carbonate, identifying the same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025. The FDA had not yet inspected the third-party manufacturing facility as part of its review of the resubmission, and raised no concerns about the drug's clinical safety or efficacy. On this news, Unicycive's stock price fell $3.01, or 39.1% (with some reports citing declines up to 46%), to close at $4.69 per share on June 30, 2026, thereby injuring investors. What is the Unicycive Therapeutics, Inc. lawsuit about? The Unicycive Therapeutics, Inc. securities lawsuit alleges that, between December 29, 2025 and June 29, 2026, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Unicycive Therapeutics, Inc.'s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose that: (1) the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices; (2) as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices; (4) as a result of the foregoing, the regulatory approval of OLC was reasonably likely to be delayed; and (5) as a result, defendants' positive statements about Unicycive Therapeutics, Inc.'s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. "The complaint filed against Unicycive Therapeutics, Inc. alleges that, among other things, the Company failed to disclose that the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices. For investors who bought during the class period, the November 2, 2026 deadline is the first major step in this case," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP. What's the next step? Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist Unicycive Therapeutics, Inc. investors in potentially pursuing claims to recover their losses. If you wish to serve as lead plaintiff in the Unicycive Therapeutics, Inc. class action, you must move the Court no later than November 2, 2026. To learn more about your rights, visit the Unicycive Therapeutics, Inc. case page, email shareholders@glancylaw.com, or call 310-201-9150 (toll-free: 888-773-9224). You may retain counsel of your choice. If you bought Unicycive Therapeutics, Inc. securities during the class period, you may take no action and remain an absent class member. No class has been certified yet in the Unicycive Therapeutics, Inc. case. Frequently Asked Questions Who is eligible? Investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. securities between December 29, 2025 and June 29, 2026 and suffered losses may be members of the proposed class in the Unicycive Therapeutics, Inc. shareholder lawsuit. Any class member may ask the court to appoint them lead plaintiff by November 2, 2026. What is a lead plaintiff? In the Unicycive Therapeutics, Inc. class action, the lead plaintiff is the investor, or group of investors, that the court appoints to represent all class members and oversee the case. Under the Private Securities Litigation Reform Act, courts generally presume the movant with the largest financial interest is the most adequate lead plaintiff. Do I have to be lead plaintiff to recover? No. A Unicycive Therapeutics, Inc. investor's ability to share in any future recovery does not depend on serving as lead plaintiff. Unicycive Therapeutics, Inc. investors may take no action and remain absent class members. What is the deadline? Motions to serve as lead plaintiff in the Unicycive Therapeutics, Inc. class action must be filed by November 2, 2026. Does it cost anything to contact Glancy or participate in this action? Glancy represents Unicycive Therapeutics, Inc. investors on a contingency fee basis, which means investors pay no attorneys' fees unless there is a recovery. Any fees are subject to court approval and are paid from the recovery. Can I choose my own lawyer? Yes. Unicycive Therapeutics, Inc. investors may retain counsel of their choice. Why work with Glancy on the Unicycive Therapeutics, Inc. lawsuit? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Unicycive Therapeutics, Inc. lawsuit. Prior results do not guarantee a similar outcome. About Glancy Prongay Wolke & Rotter LLP Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025. Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome. Related links
Contact Glancy Prongay Wolke & Rotter LLP 1925 Century Park East, Suite 2100 Los Angeles, CA 90067 Email: shareholders@glancylaw.com Telephone: 310-201-9150 | Toll-free: 888-773-9224 Follow Glancy on LinkedIn, X, or Facebook. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Glancy Prongay Wolke & Rotter LLP | ||
Company Codes: NASDAQ:UNCY |
View original content to download multimedia:
